Partner with Eclipsebio to design, evaluate, and advance optimized RNA candidates.
Contact us
Lab-in-the-loop, AI-powered drug design
Starting from a protein sequence, eNAVIGATE applies AI-driven optimization informed by experimental RNA data to design RNA therapeutic sequences with improved stability, translation, and performance. Designs are iteratively refined using lab-generated insights to reduce risk and accelerate development.
Contact usOverview
Use:
RNA therapeutic design
Typical samples:
Protein sequence
Design RNA therapeutics
with confidence
Ready to develop an optimized RNA therapy? Contact us today.
Start designingDiscuss
Our scientists work with your team to define target biology and design constraints.
Design
AI-driven optimization informed by experimental data generates and prioritizes candidate IVT RNA designs.
Validate
Top designs are iteratively evaluated using sequencing-based analytics, closing the loop between design and experiment.
Optimized designs
for therapeutic success
The following examples illustrate how eNAVIGATE generates optimized RNA designs. Contact us to learn how data-driven design can accelerate your development programs.
Design RNA therapeutics optimized for your goal
Whether you're prioritizing rapid onset for vaccines, sustained expression for protein replacement therapies, or storage stability for global distribution, eNAVIGATE balances competing constraints to deliver candidates tailored to your development strategy. Our multi-objective optimization, trained on over 29,000 experimental data points, evaluates tradeoffs across key performance dimensions to identify sequences that achieve your specific targets.
Compare design tradeoffs across multiple performance dimensions. Four sequence designs for the same protein are shown, each tailored for a specific goal such as increased manufacturability or increased protein production.
De-risk designs before manufacturing
Each eNAVIGATE design is screened using our proprietary in silico analyses to identify sequence liabilities that increase the risk of degradation or manufacturing failure. This enables high-risk candidates to be filtered out before IVT production and experimental validation.
Predicted hydrolysis hotspot scores across an RNA sequence. Red dots indicate a high risk of hydrolysis and orange dots indicate a medium risk. These predictions identify sequence liabilities that can compromise stability during storage, guiding selection of more robust designs before manufacturing.
Unlock higher therapeutic efficacy with optimized RNA designs
eNAVIGATE’s multi-objective optimization delivers higher protein expression than industry-standard and state-of-the-art models, even after a single design round.
When paired with eMERGE sequencing-based analytics, designs are further refined using experimental data, ensuring only the most effective candidates advance to experimental validation.
Protein expression levels measured 24 hours post-transfection show eNAVIGATE-optimized sequences consistently outperform industry-standard codon optimization tools and state-of-the-art foundation model designs.